Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
AssigneeJuno Therapeutics, Inc.
InventorsAshley KOEGEL, Timothy CAMPBELL, Tyler Jordan KOOP, Renee Ann Sehee RANDAZZO, Alexis MELTON, Burhan Zafar CHAUDHRY, Nivedita GULATI
Life of this patent
Estimating the term…
Abstract
Provided herein are adoptive cell therapy methods and uses involving the administration of a dose of T cells expressing a CD19-directed chimeric antigen receptor for treating subjects with autoimmune and neurological disease and disorders and related methods, compositions, uses and articles of manufacture.
Claims27
A method of treating a subject, the method comprising administering a dose of CD19-directed genetically modified T cells to a subject, wherein the T cells of the dose are positive for expression of a chimeric antigen receptor (CAR) that binds CD19 and the dose is from 1×106 to 50×106 CAR-positive T cells, wherein the subject is a subject:
- (i) having or suspected of having Myasthenia gravis (MG) and has severe disease that is refractory to three or more prior therapies for treating MG;
- (ii) having or suspected of having primary Sjogren's Disease (SiD), wherein the subject is characterized with refractory disease that is refractory to at least one prior therapy for treating SjD and/or with extraglandular disease;
- (iii) having or suspected of having ANCA-associated vasculitis (AAV);
- (iv) having or suspected of having Rheumatoid Arthritis (RA), wherein the subject has severe disease that is refractory to three or more prior therapies for treating RA;
- (v) having or suspected of having Autoimmune Encephalitis (AE);
- (vi) having or suspected of having Pemphigus:
- (vii) having or suspected of having Membranous Nephropathy (MN);
- (viii) having or suspected of having Immunoglobulin G4-related disease (IgG4-RD);
- (ix) having or suspected of having Neuromvelitis optica spectrum disorder (NMOSD);
- (x) having or suspected of having Stiff-person syndrome (SPS);
- (xi) having or suspected of having Irritable bowel disease (IBD);
- (xii) having or suspected of having Thrombotic Thrombocytopenia Purpura (TTP);
- (xiii) having or suspected of having Autoimmune hemolytic anemia (AIHA);
- (xiv) having or suspected of having Immune thrombocytopenia (ITP);
- (xv) having or suspected of having chronic Immune thrombocytopenia (cITP);
- (xvi) having or suspected of having IgA nephropathy;
- (xvii) having or suspected of having bullous pemphigoid (BP);
- or
- (xviii) having or suspected of having ulcerative colitis (UC).
A method for reducing disease activity, the method comprising administering a dose of CD19-directed genetically modified T cells to a subject, wherein the T cells of the dose are positive for expression of a chimeric antigen receptor (CAR) that binds CD19 and the dose is from 1×106 to 50×106 CAR-positive T cells, and the subject is a subject:
- (i) having or suspected of having Myasthenia gravis (MG), wherein the subject has severe disease that is refractory to three or more prior therapies for treating MG,
- (ii) having or suspected of having primary Sjogren's Disease (SjD), wherein the subject is characterized with refractory disease that is refractory to at least one prior therapy for treating SjD and/or with extraglandular disease:
- (iii) having or suspected of having ANCA-associated vasculitis (AAV);
- (iv) having or suspected of having Rheumatoid Arthritis (RA), wherein the subject has severe disease that is refractory to three or more prior therapies for treating RA:
- (v) having or suspected of having Autoimmune Encephalitis (AE):
- (vi) having or suspected of having Pemphigus:
- (vii) having or suspected of having Membranous Nephropathy (MN);
- (viii) having or suspected of having Immunoglobulin G4-related disease (IgG4-RD):
- (ix) having or suspected of having Neuromyelitis optica spectrum disorder (NMOSD);
- (x) having or suspected of having Stiff-person syndrome (SPS);
- (xi) having or suspected of having Irritable bowel disease (IBD):
- (xii) having or suspected of having Thrombotic Thrombocytopenia Purpura (TTP),
- (xiii) having or suspected of having Autoimmune hemolytic anemia (AIHA):
- (xiv) having or suspected of having Immune thrombocytopenia (ITP);
- (xv) having or suspected of having chronic Immune thrombocytopenia (cITP);
- (xvi) having or suspected of having IgA nephropathy;
- (xvii) having or suspected of having bullous pemphigoid (BP);
- or
- (xviii) having or suspected of having ulcerative colitis (UC).
3-19. (canceled)
21-24. (canceled)
A method for post-induction maintenance therapy for treating ANCA-associated vasculitis (AAV) or Autoimmune Encephalitis (AE),
- the method comprising administering a dose of CD19-directed genetically modified T cells to a subject having received an induction therapy for treating ANCA-associated vasculitis (AAV) or AE, respectively, wherein the T cells of the dose are positive for expression of a chimeric antigen receptor (CAR) that binds CD19 and the dose is from 1×106 to 50×106 CAR-positive.
26-37. (canceled)
-75. (canceled)
80-85. (canceled)
90-114. (canceled)
118-120. (canceled)
(canceled)
Dependencies are inferred from the claim text.